Research Directory

Interview with Nextech Invest: Funding the new era in oncology

Read more

Commentary: Why checkpoint inhibitors need help

Read more

Checkpoint inhibitors - A new horizon for cancer therapy

Read more

Oncology Development Review - 2013: Competition for new cancer treatments intensifies

Read more

Targeting new medicines at Roche

Read more

The Special Protocol Assessment: Regulatory success is not guaranteed

Read more

Success and failure in late-stage oncology

Read more

Why AstraZeneca is revisiting olaparib

Read more

The inventive step: antibody-drug conjugates

Read more

10-year oncology review: innovation accelerates

Read more